Despite well-established strategies to decrease the mother-to-child transmission of HIV-1, new perinatal infections continue to occur globally, reflecting marked disparities in access to health care. Once HIV-1 infection has been established in an infant, the combination of early initiation of antiretroviral therapy and prophylaxis against Pneumocystis jiroveci pneumonia is paramount to reducing disease progression. This article reviews the recommendations and evidence for the treatment of HIV-1�infected infants.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados